{"id":793524,"date":"2024-12-09T16:11:52","date_gmt":"2024-12-09T21:11:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\/"},"modified":"2024-12-09T16:11:52","modified_gmt":"2024-12-09T21:11:52","slug":"relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\/","title":{"rendered":"Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+\/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium"},"content":{"rendered":"

\nCompany to host conference call on Wednesday, December 11, 2024 at 7am ET
\n<\/h2>\n
\n

CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc.<\/a> (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that updated clinical data for RLY-2608 600mg BID + fulvestrant in patients with PI3K\u03b1-mutated, HR+, HER2- locally advanced or metastatic breast cancer will be presented at the upcoming San Antonio Breast Cancer Symposium, taking place December 10-13, 2024.<\/p>\n

Details of the RLY-2608 + fulvestrant poster presentation are as follows:
Abstract Title<\/strong>: PS7-01: Efficacy of RLY-2608, a mutant-selective PI3K\u03b1 inhibitor in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial
Abstract Number:<\/strong> SESS-2211
Session<\/strong>: Concurrent Poster Spotlight Session 7: Targeting the ER and PI3K pathway: Novel drugs and combinations
Date\/Time<\/strong>: Wednesday, December 11, 8:00-9:30 a.m. ET (7:00-8:30 a.m. CT)<\/p>\n

\n Conference Call Information<\/strong>
\n
Relay Therapeutics will host a conference call to discuss these data on Wednesday, December 11, 2024 at 7:00 a.m. ET (6:00 a.m. CT). Registration and dial-in for the conference call and webcast may be accessed through Relay Therapeutics\u2019 website under Events in the News & Events section through the following link: https:\/\/ir.relaytx.com\/news-events\/events-presentations<\/a>. An archived replay of the webcast will be available following the event.<\/p>\n

The poster will be available at the start of the session on the company\u2019s website at https:\/\/relaytx.com\/publications\/<\/a>.<\/p>\n

\n About RLY-2608<\/strong>\n <\/p>\n

RLY-2608 is the lead program in Relay Therapeutics\u2019 efforts to discover and develop mutant selective inhibitors of PI3K\u03b1, the most frequently mutated kinase in all cancers, with oncogenic mutations detected in about 14% of patients with solid tumors. RLY-2608 has the potential, if approved, to address more than 300,000 patients per year in the United States, one of the largest patient populations for a precision oncology medicine.<\/p>\n

Traditionally, the development of PI3K\u03b1 inhibitors has focused on the active, or orthosteric, site. The therapeutic index of orthosteric inhibitors is limited by the lack of clinically meaningful selectivity for mutant versus wild-type (WT) PI3K\u03b1 and off-isoform activity. Toxicity related to inhibition of WT PI3K\u03b1 and other PI3K isoforms results in sub-optimal inhibition of mutant PI3K\u03b1 with reductions in dose intensity and frequent discontinuation. The Dynamo\u00ae platform enabled the discovery of RLY-2608, the first known allosteric, pan-mutant, and isoform-selective PI3K\u03b1 inhibitor, designed to overcome these limitations. Relay Therapeutics solved the full-length cryo-EM structure of PI3K\u03b1, performed computational long time-scale molecular dynamic simulations to elucidate conformational differences between WT and mutant PI3K\u03b1, and leveraged these insights to support the design of RLY-2608. RLY-2608 is currently being evaluated in a first-in-human trial designed to treat patients with advanced solid tumors with a PIK3CA (PI3K\u03b1) mutation. For more information on RLY-2608, please visit here<\/u><\/a>.<\/p>\n

\n About Relay Therapeutics<\/strong>\n <\/p>\n

Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what\u2019s possible in drug discovery. Its Dynamo\u00ae platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics\u2019 initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com<\/a> or follow us on Twitter<\/a>.\u00a0<\/p>\n

\n Cautionary Note Regarding Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics\u2019 strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics\u2019 portfolio; the expected therapeutic benefits and potential efficacy and tolerability of RLY-2608, both as a monotherapy and in combination with other agents, and its other programs, including lirafugratinib as well as the clinical data for RLY-2608; the interactions with regulatory authorities and any related approvals; the potential market opportunity for RLY-2608; the cash runway projection and the expectations regarding Relay Therapeutics\u2019 use of capital, expenses and potential cost savings. The words \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cestimate,\u201d \u201cseek,\u201d \u201cpredict,\u201d \u201cfuture,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201ctarget\u201d and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.<\/p>\n

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of global economic uncertainty, geopolitical instability and conflicts, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy, future operations and profitability; the delay or pause of any current or planned clinical trials or the development of Relay Therapeutics\u2019 drug candidates; the risk that the preliminary or interim results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates and that interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures; Relay Therapeutics\u2019 ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled \u201cRisk Factors\u201d in Relay Therapeutics\u2019 most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics’ views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.<\/p>\n

\n Contact:<\/strong>
\n
Megan Goulart
617-322-0814
mgoulart@relaytx.com<\/u><\/a><\/p>\n

\n Media<\/strong>:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Company to host conference call on Wednesday, December 11, 2024 at 7am ET CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that updated clinical data for RLY-2608 600mg BID + fulvestrant in patients with PI3K\u03b1-mutated, HR+, HER2- locally advanced or metastatic breast cancer will be presented at the upcoming San Antonio Breast Cancer Symposium, taking place December 10-13, 2024. Details of the RLY-2608 + fulvestrant poster presentation are as follows:Abstract Title: PS7-01: Efficacy of RLY-2608, a mutant-selective PI3K\u03b1 inhibitor in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trialAbstract Number: SESS-2211Session: Concurrent Poster Spotlight Session 7: … <\/p>\n

Continue reading “Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+\/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-793524","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRelay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+\/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+\/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company to host conference call on Wednesday, December 11, 2024 at 7am ET CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that updated clinical data for RLY-2608 600mg BID + fulvestrant in patients with PI3K\u03b1-mutated, HR+, HER2- locally advanced or metastatic breast cancer will be presented at the upcoming San Antonio Breast Cancer Symposium, taking place December 10-13, 2024. Details of the RLY-2608 + fulvestrant poster presentation are as follows:Abstract Title: PS7-01: Efficacy of RLY-2608, a mutant-selective PI3K\u03b1 inhibitor in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trialAbstract Number: SESS-2211Session: Concurrent Poster Spotlight Session 7: … Continue reading "Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+\/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-09T21:11:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNjI1MSM2NjI4ODQ5IzIxOTk3ODU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+\\\/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium\",\"datePublished\":\"2024-12-09T21:11:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\\\/\"},\"wordCount\":1108,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNjI1MSM2NjI4ODQ5IzIxOTk3ODU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\\\/\",\"name\":\"Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+\\\/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNjI1MSM2NjI4ODQ5IzIxOTk3ODU=\",\"datePublished\":\"2024-12-09T21:11:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNjI1MSM2NjI4ODQ5IzIxOTk3ODU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNjI1MSM2NjI4ODQ5IzIxOTk3ODU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+\\\/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+\/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\/","og_locale":"en_US","og_type":"article","og_title":"Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+\/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium - Market Newsdesk","og_description":"Company to host conference call on Wednesday, December 11, 2024 at 7am ET CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that updated clinical data for RLY-2608 600mg BID + fulvestrant in patients with PI3K\u03b1-mutated, HR+, HER2- locally advanced or metastatic breast cancer will be presented at the upcoming San Antonio Breast Cancer Symposium, taking place December 10-13, 2024. Details of the RLY-2608 + fulvestrant poster presentation are as follows:Abstract Title: PS7-01: Efficacy of RLY-2608, a mutant-selective PI3K\u03b1 inhibitor in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trialAbstract Number: SESS-2211Session: Concurrent Poster Spotlight Session 7: … Continue reading \"Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+\/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-09T21:11:52+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNjI1MSM2NjI4ODQ5IzIxOTk3ODU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+\/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium","datePublished":"2024-12-09T21:11:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\/"},"wordCount":1108,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNjI1MSM2NjI4ODQ5IzIxOTk3ODU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\/","name":"Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+\/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNjI1MSM2NjI4ODQ5IzIxOTk3ODU=","datePublished":"2024-12-09T21:11:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNjI1MSM2NjI4ODQ5IzIxOTk3ODU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNjI1MSM2NjI4ODQ5IzIxOTk3ODU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-breast-cancer-at-2024-san-antonio-breast-cancer-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+\/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/793524","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=793524"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/793524\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=793524"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=793524"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=793524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}